CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib,ribociclib, and abemaciclib |
| |
| Institution: | 1. Division of Hematology Oncology, Department of Medicine, Columbia University Medical Center, New York, NY;2. James J. Peters VAMC, Bronx, NY;1. Department of Radiology and Nuclear Medicine, Deventer Ziekenhuis, Deventer, The Netherlands;2. Department of Radiology and Nuclear Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;1. The Scripps Research Institute, Scripps Center for Metabolomics and Mass Spectrometry, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA;2. University of Vienna, Faculty of Chemistry, Department of Food Chemistry and Toxicology, Währingerstraße 38, 1090 Vienna, Austria;3. Vienna Metabolomics Center (VIME), University of Vienna, 1090 Vienna, Austria;4. Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA;5. Nanyang Technological University, School of Civil and Environmental Engineering, 50 Nanyang Avenue, Singapore 639798, Singapore;6. Department of Surgery, Scripps Clinic Medical Group, La Jolla, CA 92037, USA;7. Department of Environmental Health Sciences, Yale School of Public Health, Yale University, 60 College Street, New Haven, CT 06520, USA;8. The Scripps Research Institute, Department of Integrative and Computational Biology, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA;1. University of California Los Angeles, Los Angeles, CA, USA;2. Irish Cooperative Oncology Research Group, Dublin, Ireland;3. Orszagos Onkologiai Intezet, Budapest, Hungary;4. Szent Margit Korhaz, Onkologia, Budapest, Hungary;5. Dnipropetrovsk Medical Academy, City Multiple-Discipline Clinical Hospital 4, Dnipropetrovsk, Ukraine;6. Municipal Treatment and Prophylactic Institution, Donetsk, Ukraine;7. Technical University of Munich, Munich, Germany;8. Comprehensive Blood and Cancer Center, Bakersfield, CA, USA;9. Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary;10. University Hospital Mainz, Mainz, Germany;11. Lviv State Oncologic Regional Treatment and Diagnostic Centre, Lviv, Ukraine;12. Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA;13. Kyiv City Clinical Oncology Centre, Kyiv, Ukraine;14. Pfizer Oncology, Milan, Italy;15. Pfizer Oncology, San Diego, CA, USA |
| |
| Abstract: | With 40,920 American women expected to die from breast cancer in 2018 and global health estimates that more than 508,000 women died in 2011 from this disease, the identification of novel therapeutic strategies for the treatment of breast cancer cannot be ignored. A breakthrough class of cancer drugs that has emerged in recent years and has had an impact in the treatment of breast cancer are the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, with palbociclib the first in class to have received regulatory approval for breast cancer. In this article we will compare and contrast three CDK4/6 inhibitors - palbociclib, ribociclib and abemaciclib - that have received regulatory approval for the treatment of metastatic breast cancer. Ribociclib and abemaciclib developed after the success of palbociclib represent examples of "me-too" therapies increasingly being deployed in oncology. |
| |
| Keywords: | Palbociclib Ribociclib Abemaciclib CDK 4 CDK 6 CDK 4 inhibitors CDK 6 inhibitors CDK4/6 inhibitors retinoblastoma retinoblastoma protein me-too cancer therapies FDA approvals |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
